A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
Primary Purpose
Degenerative Disc Disease
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
rhBMP-2/ACS/allograft bone dowel
Autogenous bone/allograft bone dowel
Sponsored by
About this trial
This is an interventional treatment trial for Degenerative Disc Disease focused on measuring symptomatic degenerative disc disease
Eligibility Criteria
Inclusion Criteria:
Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit)and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
- instability( defined as angular motion > 5° and/or translation >= 2-4mm, based on Flex/Ext radiographs);
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration or herniation; and/or
- facet joint degeneration.
- Has preoperative Oswestry score > 35.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
- Has single-level symptomatic degenerative involvement from L4 to S1.
- Is at least 18 years of age, inclusive, at the time of surgery.
- Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
- If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
- Had previous anterior spinal fusion surgical procedure at the involved level.
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids or nonsteroidal antiinflammatory drugs (this does not include low dose aspirin for prophylactic anticoagulation).
- Has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has presence of active malignancy.
- Has overt or active bacterial infection, either local or systemic.
- Is obese, i.e., weight greater than 40% over ideal for their age and height.
- Has fever (temperature> 101° F oral) at the time of surgery.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
- Is a prisoner.
- Is an alcohol and/or drug abuser.
- Is a tobacco user at the time of surgery.
- Patient has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
- Patient has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Patient has a history of exposure to injectable collagen implants.
- Patient's history includes hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
- Patient has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
- Patient has received any previous exposure to BMP.
- Patient has a history of severe allergy, an allergy to bovine products, or a history of anaphylaxis.
- Patient has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
rhBMP-2/ACS
Autogenous Bone
Arm Description
Outcomes
Primary Outcome Measures
Severity and Rate of Implant-Associated Adverse Events
Rate of Implant Revision, Removal and Supplemental Fixation Procedures
Incidence of Permanent Adverse Events
Fusion
Fusion is defined as:
Bone observed connecting with the vertebral bodies above and below either through the implants; lateral to or between the implants; or anterior/posterior to the implants.
Angulation < 5°.
Translation < 3mm.
Absence of radiolucent lines around more than 50% of either implant.
Disc Height Measurement
Disc height will be measured postoperative and compared to the preoperative measurement. Maintenance or improvement in disc height will be determined a success.
Pain/Disability Status
The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15
Neurological Status
Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale.
Secondary Outcome Measures
Nature and Frequency of Adverse Events Not Associated with the Implants
Rate of Reoperation Procedures
Hip (Donor Site) Pain Status
Patient Satisfaction/Quality of Life Status (SF-36)
Pain Status (Numerical Rating Scale)
Overall Success
A patient will be considered an overall success if all of the following conditions are met:
fusion
disc height maintenance or improvement
pain/disability (Oswestry) improvement
maintenance or improvement in neurological status
no permanent adverse event
no additional surgical procedure classified as a "failure."
Full Information
NCT ID
NCT01494428
First Posted
December 12, 2011
Last Updated
May 16, 2023
Sponsor
Medtronic Spinal and Biologics
1. Study Identification
Unique Protocol Identification Number
NCT01494428
Brief Title
A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
Official Title
A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
April 1998 (undefined)
Primary Completion Date
February 2004 (Actual)
Study Completion Date
February 2004 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spinal and Biologics
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this pilot clinical trial is to evaluate the device design as a method of facilitating spinal fusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disc Disease
Keywords
symptomatic degenerative disc disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
rhBMP-2/ACS
Arm Type
Experimental
Arm Title
Autogenous Bone
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
rhBMP-2/ACS/allograft bone dowel
Other Intervention Name(s)
Recombinant human bone morphogenetic protein-2
Intervention Description
The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
Intervention Type
Device
Intervention Name(s)
Autogenous bone/allograft bone dowel
Other Intervention Name(s)
Autograft
Intervention Description
An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
Primary Outcome Measure Information:
Title
Severity and Rate of Implant-Associated Adverse Events
Time Frame
24 month
Title
Rate of Implant Revision, Removal and Supplemental Fixation Procedures
Time Frame
24 month
Title
Incidence of Permanent Adverse Events
Time Frame
24 month
Title
Fusion
Description
Fusion is defined as:
Bone observed connecting with the vertebral bodies above and below either through the implants; lateral to or between the implants; or anterior/posterior to the implants.
Angulation < 5°.
Translation < 3mm.
Absence of radiolucent lines around more than 50% of either implant.
Time Frame
24 month
Title
Disc Height Measurement
Description
Disc height will be measured postoperative and compared to the preoperative measurement. Maintenance or improvement in disc height will be determined a success.
Time Frame
24 month
Title
Pain/Disability Status
Description
The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15
Time Frame
24 month
Title
Neurological Status
Description
Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale.
Time Frame
24 month
Secondary Outcome Measure Information:
Title
Nature and Frequency of Adverse Events Not Associated with the Implants
Time Frame
24 month
Title
Rate of Reoperation Procedures
Time Frame
24 month
Title
Hip (Donor Site) Pain Status
Time Frame
24 month
Title
Patient Satisfaction/Quality of Life Status (SF-36)
Time Frame
24 month
Title
Pain Status (Numerical Rating Scale)
Time Frame
24 month
Title
Overall Success
Description
A patient will be considered an overall success if all of the following conditions are met:
fusion
disc height maintenance or improvement
pain/disability (Oswestry) improvement
maintenance or improvement in neurological status
no permanent adverse event
no additional surgical procedure classified as a "failure."
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit)and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:
instability( defined as angular motion > 5° and/or translation >= 2-4mm, based on Flex/Ext radiographs);
osteophyte formation;
decreased disc height;
thickening of ligamentous tissue;
disc degeneration or herniation; and/or
facet joint degeneration.
Has preoperative Oswestry score > 35.
Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
Has single-level symptomatic degenerative involvement from L4 to S1.
Is at least 18 years of age, inclusive, at the time of surgery.
Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.
Exclusion Criteria:
Had previous anterior spinal fusion surgical procedure at the involved level.
Has a condition which requires postoperative medications that interfere with fusion, such as steroids or nonsteroidal antiinflammatory drugs (this does not include low dose aspirin for prophylactic anticoagulation).
Has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
Has presence of active malignancy.
Has overt or active bacterial infection, either local or systemic.
Is obese, i.e., weight greater than 40% over ideal for their age and height.
Has fever (temperature> 101° F oral) at the time of surgery.
Is mentally incompetent. If questionable, obtain psychiatric consult.
Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
Is a prisoner.
Is an alcohol and/or drug abuser.
Is a tobacco user at the time of surgery.
Patient has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
Patient has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
Patient has a history of exposure to injectable collagen implants.
Patient's history includes hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
Patient has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
Patient has received any previous exposure to BMP.
Patient has a history of severe allergy, an allergy to bovine products, or a history of anaphylaxis.
Patient has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
12. IPD Sharing Statement
Learn more about this trial
A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
We'll reach out to this number within 24 hrs